Array BioPharma Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
211.67 M |
Public Float |
146.57 M |
Array BioPharma Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.59 |
Market Cap |
$10.46 B |
Shares Outstanding |
223.1 M |
Public Float |
216.9 M |
Address |
3200 Walnut Street Boulder Colorado 80301 United States |
Employees | - |
Website | http://www.arraybiopharma.com |
Updated | 07/08/2019 |
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. |